When was Lumos Pharma founded?

Lumos Pharma was founded in 1999 and raised its 1st funding round 9 years after it was founded.

Where is Lumos Pharma located?

Lumos Pharma is headquartered in Austin, United States. It is registered at 2503 S LOOP DR STE 5100,AMES,IA,50010,0.

How many employees does Lumos Pharma have?

As of Sep 30, 2026, the latest employee count at Lumos Pharma is 50.

Is Lumos Pharma a funded company?

Lumos Pharma is a funded company, having raised a total of $48M across 9 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 17, 2008.

When was the latest funding round of Lumos Pharma?

Lumos Pharma's latest funding was a $***** Series B round on Sep 08, 2016, with participation from 1 investor.

Where does Lumos Pharma rank among its competitors?

Lumos Pharma ranks 88th amongst 280 active competitors, of which 77 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Lumos Pharma?

Lumos Pharma's top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, BridgeBio secured the most recent funding round in April, 2024.

Lumos Pharma - 2026 Company Profile, Funding, Competitors & Financials

Lumos Pharma is a series B company based in Austin (United States), founded in 1999. It operates as a Biopharmaceutical company transforming lives through therapeutics for rare diseases. Lumos Pharma has raised $48M in funding from investors like New Enterprise Associates, Sante Ventures and Deerfield. The company has 280 active competitors, including 77 funded and 98 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.

Company Details

Biopharmaceutical company transforming lives through therapeutics for rare diseases. Focused on developing innovative therapies for unmet medical needs, particularly in pediatric growth hormone deficiency (PGHD). The company is dedicated to helping patients and families through advocacy and compassionate use programs. They are committed to advancing clinical research and fostering partnerships to bring novel treatments to market. The company's pipeline includes LUM-201, an oral therapeutic candidate for PGHD. They are involved in clinical trials and presentations to share their research findings. The company emphasizes a culture of collaboration and innovation, seeking to make a significant impact on the lives of individuals affected by rare conditions.

Website: lumos-pharma.com
Social
Registered Address: 2503 S LOOP DR STE 5100,AMES,IA,50010,0

Key Metrics

Founded Year

1999

Location

Austin, United States

Stage

Series B

Total Funding

$48M in 9 rounds

Latest Funding Round

Series B, Sep 08, 2016, $*****

Investors

New Enterprise Associates & 9 more

Ranked

88^th among 280 active competitors

Employee Count

50 as on Sep 30, 2026

Similar Companies

BridgeBio & 314 more

View Lumos Pharma's full profile

Lumos Pharma is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Lumos Pharma, Inc. CIN: 32053894724 , United States, Active	May 09, 2014	-	-	-
LUMOS PHARMA, INC. CIN: 42-1491350 , United States, Active		-	28 (As on Dec 31, 2020)	-

Lumos Pharma has raised a total funding of $48M over 9 rounds. Its first funding round was on Sep 17, 2008. Its latest funding round was a Series B round on Sep 08, 2016 for $*****. 1 investor participated in its latest round. Lumos Pharma has 10 institutional investors.

Here is the list of recent funding rounds of Lumos Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 08, 2016	8554133	Series B	4011875	6463061	4806775	7764695
Apr 18, 2016	9168399	Series B	6000811	7126250	8350189	New Enterprise Associates & 4 more
May 04, 2015	4398815	Grant (prize money)	8587622	1966469	6968729	Wellcome Trust

Access funding benchmarks and valuations. Sign up today!

View details of Lumos Pharma's funding rounds and investors

Lumos Pharma's employee count trend

Lumos Pharma has 50 employees as of Sep 26. Here is Lumos Pharma's employee count trend over the years:

Uncover Lumos Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lumos Pharma include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Lumos Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
10th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
88th	Lumos Pharma 1999, Austin (United States), Series B	Biopharmaceutical company transforming lives through therapeutics for rare diseases	$48M	Deerfield, Roche Enterprises & 8 others	52/100